The efficacy profile of vilazodone, a novel antidepressant for the treatment of major depressive disorder

Current Medical Research and Opinion

Volumn 28, Issue 1, 2012, Pages 27-39

  Reed, Carol R ^a   Kajdasz, Daniel K ^a   Whalen, Heidi ^a   Athanasiou, Maria C ^b   Gallipoli, Susan ^a   Thase, Michael E ^c  

^a Subsidiary of Forest Laboratories Inc   (United States)

^b Athanasiou Consulting LLC   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Antidepressant; Depression; Efficacy; Major depressive disorder; Vilazodone

Indexed keywords

PLACEBO; VILAZODONE;

ADULT; AGED; ANTIDEPRESSANT ACTIVITY; ARTICLE; CLINICAL GLOBAL IMPRESSION SCALE; CONTROLLED STUDY; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; HAMILTON ANXIETY SCALE; HAMILTON SCALE; HUMAN; MAJOR DEPRESSION; MALE; MONTGOMERY ASBERG DEPRESSION RATING SCALE; OPEN STUDY; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; RANDOMIZED CONTROLLED TRIAL (TOPIC); UNSPECIFIED SIDE EFFECT;

ADOLESCENT; ADULT; AGED; ANTIDEPRESSIVE AGENTS; BENZOFURANS; CLINICAL TRIALS, PHASE III AS TOPIC; DEPRESSIVE DISORDER, MAJOR; DOUBLE-BLIND METHOD; FEMALE; FOLLOW-UP STUDIES; HUMANS; INDOLES; MALE; MIDDLE AGED; PIPERAZINES; PLACEBOS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TIME FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84855946303     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007995.2011.628303     Document Type: Article

References (21)

1. Kessler RC, Berglund P, Demler O, et al. The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R). JAMA 2003;289:3095-105 (Pubitemid 37432885)
2. Katon W, Lin EH, Kroenke K. The association of depression and anxiety with medical symptom burden in patients with chronic medical illness. Gen Hosp Psychiatry 2007;29:147-55
3. Gelenberg AJ. The prevalence and impact of depression. J Clin Psychiatry 2010;71:e06
4. Katon WJ. Clinical and health services relationships between major depression, depressive symptoms, and general medical illness. Biol Psychiatry 2003;54:216-26 (Pubitemid 37270614)
5. Egede LE. Major depression in individuals with chronic medical disorders: prevalence, correlates and association with health resource utilization, lost productivity and functional disability. Gen Hosp Psychiatry 2007;29:409-16 (Pubitemid 47410305)
6. Mathers C, Loncar D. Projections of global mortality and burden of disease from 2002 to 2030. PLoS Med 2006;3:e442
7. Keitner GI, Solomon DA, Ryan CE. STAR*D: have we learned the right lessons? Am J Psychiatry 2008;165:133-4
8. Rush AJ, Trivedi MH, Wisniewski SR, et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am J Psychiatry 2006;163:1905-17 (Pubitemid 44807782)
9. Hughes ZA, Starr KR, Langmead CJ, et al. Neurochemical evaluation of the novel 5-HT1A receptor partial agonist/serotonin reuptake inhibitor, vilazodone. Eur J Pharmacol 2005;510:49-57 (Pubitemid 40312389)
10. Dawson LA, Watson JM. Vilazodone: a 5-HT1A receptor agonist/serotonin transporter inhibitor for the treatment of affective disorders. CNS Neuroscience and Therapeutics 2009;15:107-17
11. Rickels K, Athanasiou M, Reed C. Vilazodone, a novel, dual-acting antidepressant: current status, future promise and potential for individualized treatment of depression. Personalized Medicine 2009;6:216-24
12. Kehne JH, Bartoszyk GD, Greiner HE, et al. In vitro characterization of vilazodone as a dual-acting serotonin reuptake inhibitor and 5-HT1A receptor partial agonist. Poster presented at: 65th Annual Meeting of the Society of Biological Psychiatry Meeting; May 20-22, 2010, New Orleans, LA, USA
13. Rickels K, Athanasiou M, Robinson DS, et al. Evidence for efficacy and tolerability of vilazodone in the treatment of major depressive disorder: a randomized, double-blind, placebo-controlled trial. J Clin Psychiatry 2009; 70:326-33
14. Khan A, Cutler AJ, Kajdasz DK, et al. Efficacy and tolerability of vilazodone, a dual-acting serotonergic antidepressant, in the treatment of patients with major depressive disorder (MDD). Poster presented at: 163rd Annual Meeting of the American Psychiatric Association; May 22-26, 2010, New Orleans, LA, USA
15. Robinson DS, Kadjdaz DK, Gallipoli S, et al. A 1-year open-label study assessing the safety and tolerability of vilazodone in patients with major depressive disorder. J Clin Psychopharmacol 2011 Aug 24 [Epub ahead of print]
16. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision, Washington, DC: American Psychiatric Association, 2000
17. Sheehan DV, Lecrubier Y, Harnett Sheehan K, et al. The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry 1998;59(Suppl 20):22-33 (Pubitemid 29001829)
18. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry 1960;23:56-62
19. Montgomery SA,A° sberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry 1979;134:382-9 (Pubitemid 9136500)
20. Hamilton M. The assessment of anxiety states by rating. Br J Med Psychol 1959;32:50-5
21. Guy W. Clinical Global Impressions (028-CGI). In: Guy W ECDEU Assessment Manual for Psychopharmacology. Rockville, MD: National Institute of Mental Health, 1976:216-22